Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Stage of Development | 8 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Therapy Area | 9 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Indication | 10 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Companies | 13 | 2 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Therapeutics Assessment | 15 | 4 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Companies Involved in Therapeutics Development | 19 | 11 |
| Advinus Therapeutics Ltd | 19 | 1 |
| Amgen Inc. | 20 | 1 |
| Hua Medicine (Shanghai) Ltd. | 21 | 1 |
| LG Life Science LTD. | 22 | 1 |
| Ligand Pharmaceuticals, Inc. | 23 | 1 |
| Novartis AG | 24 | 1 |
| Poxel SA | 25 | 1 |
| Takeda Pharmaceutical Company Limited | 26 | 1 |
| Teijin Pharma Limited | 27 | 1 |
| vTv Therapeutics Inc | 28 | 1 |
| Yuhan Corporation | 29 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Drug Profiles | 30 | 13 |
| AM-9514 Drug Profile | 30 | 1 |
| GKM-001 Drug Profile | 31 | 1 |
| LC-280391 Drug Profile | 32 | 1 |
| LCZ-960 Drug Profile | 33 | 1 |
| Sinogliatin Drug Profile | 34 | 2 |
| Small Molecule to Activate Glucokinase for Type 2 Diabetes Drug Profile | 36 | 1 |
| Small Molecules to Activate Glucokinase for Type 2 Diabetes Drug Profile | 37 | 1 |
| Small Molecules to Activate Glucokinase for Type 2 Diabetes Drug Profile | 38 | 1 |
| TMG-123 Drug Profile | 39 | 1 |
| TTP-399 Drug Profile | 40 | 2 |
| YH-GKA Drug Profile | 42 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Dormant Projects | 43 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Discontinued Products | 44 | 1 |
| Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Featured News &Press Releases | 45 | 10 |
| Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity | 45 | 1 |
| Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes | 45 | 1 |
| Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial | 46 | 1 |
| Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes | 46 | 1 |
| Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug | 47 | 1 |
| Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control | 48 | 1 |
| Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics | 49 | 1 |
| Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation &Commences Phase 1b Trials in Diabetes Patients | 50 | 2 |
| Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial | 52 | 1 |
| Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013 | 52 | 1 |
| Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial | 52 | 1 |
| Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes | 53 | 1 |
| Sep 07, 2010: GKM-001 Completes Phase I Single Ascending Dose Study | 53 | 2 |
| Appendix | 55 | 2 |
| Methodology | 55 | 1 |
| Coverage | 55 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 56 | 1 |